此延伸研究的目的是为持续耐受并从接受venetoclax中获益的受试者提供venetoclax，并获取长期安全性数据。
适应症：Chronic Lymphocytic Leukemia、Acute Myeloid Leukemia、Multiple Myeloma、Non-Hodgkin's Lymphoma、Acute Lymphoblastic Leukemia、Cancer
入组条件
纳入标准
- Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.
排除标准
- \- None.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。